Marimed (MRMD) Common Equity (2011 - 2026)

Marimed (MRMD) has 16 years of Common Equity data on file, last reported at $46.5 million in Q1 2026.

• Common Equity for Q1 2026 came in at $46.5 million, down 19.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $46.5 million (down 19.56% YoY), and the FY2025 annual result was $50.0 million, down 14.58% from the prior year.
• Common Equity declined to $46.5 million in Q1 2026 per MRMD's latest filing, from $50.0 million in the prior quarter.
• Over five years, Common Equity peaked at $80.9 million in Q2 2023 and troughed at $43.6 million in Q1 2022.
• A 5-year average of $60.1 million and a median of $57.8 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2025: Common Equity soared 196.47% in 2022, then slipped 19.93% in 2025.
• A 5-year view of Common Equity shows it stood at $57.3 million in 2022, then grew by 20.2% to $68.9 million in 2023, then fell by 15.01% to $58.5 million in 2024, then dropped by 14.58% to $50.0 million in 2025, then slipped by 6.99% to $46.5 million in 2026.
• Business Quant data shows MRMD's Common Equity at $46.5 million in Q1 2026, $50.0 million in Q4 2025, and $54.3 million in Q3 2025.